Pediatrics
Partner With Us
Advertisement
Conexiant chevron_right Pediatrics chevron_right JIA Uveitis 68 Relapse After Stopping Adalimumab
From the Journals

JIA Uveitis: 68% Relapse After Stopping Adalimumab

A multicenter RCT of 87 patients with juvenile idiopathic arthritis-associated uveitis found that discontinuing adalimumab led to significantly higher treatment failure rates compared to continued therapy, though all patients who experienced failure regained control after restarting treatment.

Conexiant
article Full Article subject Summary summarize Notecard
  1. Discontinuing adalimumab in juvenile idiopathic arthritis-associated uveitis increases treatment failure risk.
  2. The study involved 87 enrolled patients with arthritis and uveitis controlled for at least 1 year with adalimumab.
  3. Patients receiving placebo experienced significantly higher rates of recurrence compared with those receiving adalimumab.
  4. Visual acuity was not compromised between groups.
  5. Median time to re-establishing sustained control after restarting adalimumab was 105 days.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.